BioinvestGPT

Compass's COMPANION-002 just confirmed a sealed verdict 540 days in the making. Eighteen months ago, an independent BVCT head-to-head — Tovecimig + paclitaxel vs paclitaxel monotherapy in 2L+ advanced biliary tract cancer — was sealed on 3 November 2024 (No. 1195), run from outside the sponsor's data against the publicly registered protocol NCT05506943 at https://lnkd.in/gHXX2ZzQ. The sealed verdict: PFS wins on the primary endpoint; OS non-superior to paclitaxel alone; intra-tumoral DLL4 expression flagged as the crucial OS stratification differentiator. Last week, COMPANION-002 confirmed it line for line: PFS HR 0.44, p<0.0001 on the primary endpoint, OS HR 1.05 in the unstratified arm. This is the tenth sealed BVCT run on PFS–OS discordance, and the tenth time the readout matched. Average lead across the ten: 284 days. Drug MoA + publicly registered protocol only. Your patient data stays yours. For every Phase 2/3 advancement gate that carries a PFS–OS discordance question — the answer can sit on a sealed prospective record before the readout arrives. The case of record now spans ten. See the proof at https://lnkd.in/eFV9DdKs. Clinically all-seeing before decisions. Earlier BVCT is kinder for patients. #BioinvestGPT #VirtualClinicalTrial #ProspectivePrediction #BiliaryTractCancer #DrugDevelopment #ClinicallyAllSeeing

Clinically all-seeing before decisions. Earlier BVCT is kinder for patients. Every pharma decision-maker's heart aspires to honor patients’ lives, be worthy of their hope, respect their time, and respond to their pain. Data-driven AI does not understand complex human biology, keeps pharma decision-makers clinically blind until it's too late for patients. The clinical superintelligence - BeatSoC Virtual Clinical Trials (BVCTs) - empower pharma decision-makers to deliver-by becoming clinically all-seeing before every GO/NO-GO decision that matters for patients. Below is 1 of the 600+ evidence for the pharma-audited reliability of BVCTs is 100% prospectively validated: On 19 January 2025, BVCT predicted that zanidatamab triplet for 1L HER2-positive gastric cancer would deliver Moderately Superior OS to standard of care. On 17 November 2025, the readout of HERIZON-GEA-01 confirmed it — 302 days later. BVCT proprietary knowledge of human biology enables 96% prospective clinical benefit prediction accuracy across 580 of 604 then-ongoing human clinical trials. BVCT never need to access patient data. Ever. Which of your own programs would you most want 302 days of advance clarity on? The prospective record is open — search any NCT ID at data.bioinvestgpt.com. #BioinvestGPT #VirtualClinicalTrial #ProspectivePrediction #HER2 #DrugDevelopment #ClinicallyAllSeeing